This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage  potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing,during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects.The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.

Introduction

Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy
Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies
Cardiovascular Damage Induced by Radiotherapy
Cardiovascular Damage Induced by Anti-VEGF Therapy
Cardiovascular Damage Induced by Anti-BCR-ABL TKIs
Heart Failure and Left Ventricular Dysfunction
Coronary Artery Disease
Peripheral Artery Disease and Stroke
Valvular Heart Disease
Arterial Hypertension
Atrial Fibrillation in Cancer
Management of QT Prolongation Induced by Anti-cancer Drugs
Pulmonary Hypertension Induced by Anti-cancer Drugs
Venous Thromboembolism
Early Detection of Cardiac Damage
Diagnosis of Cardiac Damage: Role of Stress Echo
Early Detection and Monitoring of Vascular Damage
Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy
Cardiovascular Damage in Clinical Trials.